Clinical Study

Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS

Kim Forrester-Dumont,1 Ovidiu Galescu,2 Andrey Kolesnikov,2 Nouhad Raissouni,2 Amrit Bhangoo,2 Svetlana Ten,2 and Amy Suss1

1 Division of Adolescent Medicine, The Children’s Hospital at SUNY Downstate, Brooklyn, NY, USA
2 Pediatric Endocrinology Division, Infant’s and Children’s Hospital of Brooklyn at Maimonides and the Children’s Hospital at SUNY Downstate, Brooklyn, NY 11219, USA

Correspondence should be addressed to Svetlana Ten, tenlana@aol.com

Received 20 November 2011; Revised 22 January 2012; Accepted 23 January 2012

Academic Editor: Faustino R. Pérez-López

Copyright © 2012 Kim Forrester-Dumont et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Underlying insulin resistance and/or obesity has clearly been implicated in the development of metabolic syndrome in adolescents and young adults with polycystic ovarian syndrome (PCOS). It is not clear however what role hyperandrogenism has on the development of metabolic syndrome or its role on those metabolic parameters associated with metabolic syndrome.

Methods. We studied 107 adolescent girls; 54 had PCOS according to NIH criteria. Data was obtained for systolic and diastolic blood pressure (SBP and DBP), body mass index (BMI), total testosterone (T), luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, fasting lipid profile, and glucose. The PCOS group was divided initially into subgroups according to BMI (kg/m2), then based on T (ng/dL) levels as follows: High Testosterone PCOS (HT), Intermediate Testosterone PCOS (IT), Obese and Normal Testosterone (ONT), and Lean and normal T (Control, C).

t-test analysis was performed in between all the groups.

Results. There was no statistical difference between HT and IT, HT and ONT, or IT and ONT in SBP, DBP, fasting blood glucose, lipid panel, LH, FSH, and prolactin levels. The control group had lower SBP and BMI comparing with ONT, IT, and HT groups. There were no statistical differences found in DBP, fasting blood glucose, lipid panel, LH, FSH, or Prolactin.

Conclusion. Metabolic profile in adolescent girls with PCOS is not affected by either the presence of hyperandrogenism or the degree of hyperandrogenism.

1. Introduction

Polycystic Ovarian Syndrome (PCOS) is a heterogeneous group of conditions that include anovulation, hyperandrogenism, and polycystic ovaries. PCOS is often associated with both obesity and metabolic syndrome.

The NIH-National Institute of Child Health and Human Development Conference of PCOS originally recommended that the major criteria for PCOS should include hyperandrogenism and/or hyperandrogenemia, oligoovulation, ultrasound pattern of polycystic ovaries and the exclusion of other known disorders. A PCOS diagnosis is considered a hyperandrogenic disorder of exclusion with an ovarian etiology. In 2003, the Rotterdam consensus expanded the diagnostic criteria to include at least two of the following three features: clinical and/or biochemical hyperandrogenism, oligoanovulation, and polycystic ovaries, excluding any other endocrinopathies [1]. In 2006, the Androgen Excess-PCOS society recommended that PCOS be defined by clinical and/or biochemical hyperandrogenism, with either oligoanovulation and/or polycystic ovaries, excluding related disorders [2].

The circulating total and free testosterone and dehydroepiandrosterone sulfate (DHEAS) levels are elevated in 50–75% of women with PCOS, if high quality assays are used [3]. Androgen excess is considered by some investigators to be the key feature of PCOS; however, only 80–85% of women with clinical hyperandrogenism have PCOS [4, 5]. Despite this evidence hyperandrogenism remains an important part of PCOS and is included as major set of symptoms in both
NIH and Rotterdam criteria [1]. According to the NIH criteria PCOS affects 6–10% of women of the child bearing age [6–10]. As per the broader Rotterdam criteria even more individuals can be classified as having PCOS [11]. Therefore PCOS becomes one of the most common human disorders and the single most common endocrinopathy in women of reproductive age.

According to a common view PCOS is a multifactorial and polygenic in nature [1, 11, 12]. Up to now multiple studies failed to identify genes responsible for PCOS and condition [12].

Metabolic syndrome is associated with development of hyperandrogenism and PCOS. But the question still remains unanswered as to what is primary or secondary: metabolic syndrome or hyperandrogenism. There is an opinion and data suggests that testosterone was significantly related to metabolic syndrome and its components in obese adolescent girls [13, 14]. Other data reveals that in obese adolescent girls PCOS does not add additional risk of further complications of metabolic syndrome [15, 16]. PCOS adolescent girls have been found to have increased visceral abdominal fat [16, 17], but there was no correlation between visceral abdominal tissue and total testosterone or free androgen index [15, 16].

There are case studies that show that low HDL cholesterol is the criterion which best explains the high prevalence of the metabolic syndrome in PCOS subjects which, in turn, is influenced by hyperinsulinemia, rather than by hyperandrogenemia [18].

In both animal and human models the associations between serum testosterone and insulin resistance or metabolic syndrome/type 2 diabetes/PCOS risk in women were demonstrated, but their cross-sectional nature did not allow conclusions about causality [19].

As such the aim of our study was to find out whether elevated testosterone level impacts the presentation of metabolic syndrome in obese adolescent girls.

2. Materials and Methods

2.1. Patients. We enrolled 107 adolescent girls from the pediatric endocrinology clinics and adolescent clinic at SUNY Downstate Medical Center. PCOS group was selected based on NIH criteria including irregular menses and clinical and biochemical signs of hyperandrogenism. The study was approved by IRB of SUNY Downstate Medical Center.

2.2. Exclusion Criteria. Congenital Adrenal Hyperplasia, Cushing’s Syndrome, severe insulin resistance, and androgen-secreting tumors were excluded in all cases. Also excluded from this study were patients under treatment with any lipid-lowering drugs, insulin sensitizers (e.g., Metformin), or Inositol supplements.

The control group was selected from the adolescent clinic patients seen for routine health examinations. The majority of the patients were of African American descent.

The patients were divided into 4 subgroups.

(1) High Testosterone (HT): patients that met the NIH and Rotterdam Criteria for PCOS and had Total Testosterone > 90 ng/dL;

(2) Intermediate Testosterone (IT): patients that met the NIH and Rotterdam Criteria for PCOS and had Total Testosterone in range 51–90 ng/dL;

(3) Obese and Normal Testosterone (ONT): patients that did not fulfill the NIH and Rotterdam Criteria for PCOS and had BMI > 95th percentile, total testosterone < 50 ng/dL;

(4) Controls (C) Patients that did not fulfill the NIH and Rotterdam Criteria for PCOS and had BMI < 95th percentile, Total Testosterone < 50 and regular periods, and did not meet any of the exclusion criteria.

The group of 54 girls who had PCOS according to NIH criteria including irregular period or amenorrhea and increased level of testosterone was subdivided into 2 subgroups with (a) 23 patients with high level of testosterone (T) and (b) 31 patients with intermediate level of testosterone (T).

As a control we assigned 15 patients who had normal BMI and normal level of testosterone.

The ONT group consisted of 38 patients who had elevated BMI and normal testosterone.

Characteristics of the patients are detailed in Table 1.

2.3. Measurements Methods. Data was obtained for blood pressure, BMI, testosterone, LH, FSH, prolactin, fasting lipid profile, and glucose. BMI was calculated as weight
SBP

HT: high testosterone
IT: intermediate testosterone
ONT: obese normal testosterone
C: controls

Figure 1: Systolic Blood Pressure—distribution among the groups.
HT: High Testosterone, IT: Intermediate Testosterone; ONT: Obese Normal Testosterone; C: Controls.

(kg)/(height (cm))² and BMI above 95th percentile according to the CDC [20], BMI charts was defined as obese.

Testosterone was determined by chemiluminescent immunooassay methodology; high testosterone was defined as testosterone above 90 ng/dL and high intermediate as between 51 and 90 ng/dL.

2.4. Statistical Analyses. Two-sample t-test assuming unequal variances analysis was performed to compare the means of the studied parameter between the 4 groups.

Multivariate logistic regression analysis was done for testosterone levels and LH, FSH, prolactin, lipid profile, fasting glucose, SBP, DBP, and BMI. For the statistical analysis we used the SPSS 19.0 software.

3. Results

There was no statistical difference between the high testosterone group HT and the other groups IT and ONT in SBP, DBP, fasting blood glucose, lipid panel, LH, FSH, and prolactin.

Furthermore our analyses did not yield any statistically significant difference between the intermediate testosterone group IT and ONT in any of the studied parameters (Table 1).

The control group had lower SBP and BMI comparing with the other groups but no statistical difference was found in DBP, fasting blood glucose, lipid panel, LH, FSH, or prolactin (Figure 1). The regression analysis did not yield any correlation between the testosterone levels and any of the other parameters.

The regressions were run both for the entire population studied and for each separate subgroup.

Table 2: Correlations of BMI with the studied parameters.

| Parameter     | r    | p value |
|---------------|------|---------|
| SBP           | 0.5  | <0.001  |
| DBP           | 0.23 | <0.001  |
| Total cholesterol | 0.25 | <0.01   |
| HDL           | 0.27 | <0.01   |
| LDL           | 0.33 | <0.01   |
| LH            | 0.19 | 0.03    |
| Triglycerides | 0.06 | 0.56    |
| FSH           | 0.06 | 0.49    |
| Prolactin     | 0.08 | 0.35    |

BMI: Body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, LH: Luteinising hormone, FSH: Follicle-stimulating hormone.

BMI had statistically significant correlations with SBP, DBP, cholesterol profile, and LH but no correlation was seen for triglycerides, FSH, and prolactin (Table 2).

4. Discussion

Upon review of the literature, several studies suggest that PCOS and high testosterone is an additional risk and is significantly related to metabolic syndrome and its sequelae in obese adolescent girls [21–25]. PCOS in adolescent patients has been found to have increased visceral abdominal fat [17], but there was no correlation between visceral abdominal tissue and total testosterone or free androgen index [15]. An elevated risk profile for cardiovascular morbidity was demonstrated in PCOS patients, mainly attributed to increases in type 2 diabetes, dyslipidemia, and hypertension [18, 26, 27] which might constitute a cofounder when studying the correlation between hyperandrogenism and the risk of metabolic syndrome in PCOS.

However, contrary with such studies [28, 29], we found that there were no significant differences in the relationship between the degree of hyperandrogenism and the metabolic parameters associated with metabolic syndrome. The level or degree of hyperandrogenism did not alter the metabolic parameters in our study group.

While it is known that PCOS is significantly more prevalent among obese patients [30] and altered metabolic parameters are directly associated to degrees of BMI [31], there is still no consensus as to the question of what is primary or secondary metabolic syndrome or hyperandrogenism. PCOS is polygenic condition and may be influenced by environmental factors like diet and lifestyle. In first-degree female relatives of PCOS patients, it has been documented to be an increase in adrenal androgens and insulin resistance in these girls thus suggesting a genetic component. However, to date, there is no clearly defined genetic etiology that is associated with PCOS and it is not clear whether hyperandrogenism is involved in the pathogenesis of this disorder.

We may speculate that increased rate of metabolic syndrome among obese girl with PCOS may be confounded with obesity rather than hyperandrogenism. Another reason for
lack of correlation between PCOS and metabolic syndrome in adolescent girls may be that patients should be exposed to androgens longer to develop metabolic abnormalities in the adult age.

It is important for further studies to investigate the effects of prolonged exposure to high circulating androgens mainly in lean PCOS patients and the progression of this phenotype to metabolic syndrome. It is our belief that there may be an associated pathophysiological link with obesity, particularly visceral adiposity, and related adipose tissue factors, coagulation abnormalities, or insulin resistance [16, 19, 32] that may independently increase cardiovascular risk rather than a direct association of hyperandrogenism with metabolic syndrome morbidity.

Our study was limited by its small sample size. There can be limitations arising from the sample collection method or the chemiluminescent immunoassay method used to determine testosterone levels. However, this is unlikely to alter the main conclusions.

References
[1] B. C. J. M. Fauser, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 19–25, 2004.
[2] R. Aziz, E. Carmina, D. Dewailly et al., “Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4237–4245, 2006.
[3] A. Huang, K. Brennan, and R. Aziz, “Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria,” Fertility and Sterility, vol. 93, no. 6, pp. 1938–1941, 2010.
[4] R. Aziz, E. Carmina, D. Dewailly et al., “The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report,” Fertility and Sterility, vol. 91, no. 2, pp. 456–488, 2009.
[5] R. Aziz, L. A. Sanchez, E. S. Knochenhauer et al., “Androgen excess in women: experience with over 1000 consecutive patients,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 453–462, 2004.
[6] M. Asunciòn, R. M. Calvo, J. L. San Millà N, J. Sancho, S. Avila, and H. F. Escobar-Morreale, “A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 7, pp. 2434–2438, 2000.
[7] R. Aziz, K. S. Woods, R. Reyna, T. J. Key, E. S. Knochenhauer, and B. O. Yıldız, “The prevalence and features of the polycystic ovary syndrome in an unselected population,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2745–2749, 2004.
[8] E. Diamanti-Kandarakis, C. R. Kouli, A. T. Bergiele et al., “A survey of the polycystic ovary syndrome in the Greek Island of Lesbos: hormonal and metabolic profile,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 11, pp. 4006–4011, 1999.
[9] E. S. Knochenhauer, T. J. Key, M. Kahsar-Miller, W. Waggoner, L. R. Boots, and R. Aziz, “Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 9, pp. 3078–3082, 1998.
[10] K. F. Michelmore, A. H. Balen, D. B. Dunger, and M. P. Vessey, “Polycystic ovaries and associated clinical and biochemical features in young women,” Clinical Endocrinology, vol. 51, no. 6, pp. 779–786, 1999.
[11] F. J. Broekmans, E. A. H. Knaufl, O. Valkenburg, J. S. Laven, M. J. Eijkmans, and B. C. J. M. Fauser, “PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors,” An International Journal of Obstetrics and Gynecology, vol. 113, no. 10, pp. 1210–1217, 2006.
[12] L. G. Nardo, S. Patchava, and I. Laing, “Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications,” Panminerva Medica, vol. 50, no. 4, pp. 267–278, 2008.
[13] G. De Sousa, C. Brodowski, M. Kleber, R. Wunsch, and T. Reinehr, “Association between androgens, intima-media thickness and the metabolic syndrome in obese adolescent girls,” Clinical Endocrinology, vol. 72, no. 6, pp. 770–774, 2010.
[14] F. Fruzzetti, D. Perini, V. Lazzarini, D. Parrini, and A. R. Genazzani, “Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome,” Gynecological Endocrinology, vol. 25, no. 5, pp. 335–343, 2009.
[15] B. Rossi, S. Sukalich, J. Droz et al., “Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 12, pp. 4780–4786, 2008.
[16] C. N. Wijeyaratne, R. D. A. Seneviratne, S. Dahanayake et al., “Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic,” Human Reproduction, vol. 26, no. 1, pp. 202–213, 2011.
[17] R. Jeffrey Chang and M. S. Cofer, “Polycystic ovary syndrome: early detection in the adolescent,” Clinical Obstetrics and Gynecology, vol. 50, no. 1, pp. 178–187, 2007.
[18] A. Gambineri, A. Repaci, L. Patton et al., “Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 19, no. 11, pp. 797–804, 2009.
[19] A. Corbould, “Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?” Diabetes/Metabolism Research and Reviews, vol. 24, no. 7, pp. 520–532, 2008.
[20] http://www.cdc.gov/obesity/defining.html.
[21] G. De Sousa, C. Brodowski, M. Kleber, R. Wunsch, and T. Reinehr, “Association between androgens, intima-media thickness and the metabolic syndrome in obese adolescent girls,” Clinical Endocrinology, vol. 72, no. 6, pp. 770–774, 2010.
[22] R. Schroff, C. H. Syrop, W. Davis, B. J. Van Voorhis, and A. Dokras, “Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria,” Fertility and Sterility, vol. 88, no. 5, pp. 1389–1395, 2007.
[23] R. P. Kaufman, T. E. Baker, V. M. Baker, P. DiMarino, and V. D. Castracane, "Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria," American Journal of Obstetrics and Gynecology, vol. 198, no. 6, pp. 670.e1–670.e10, 2008.
[24] E. Diamanti-Kandarakis and D. Panidis, “Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS,” Clinical Endocrinology, vol. 67, no. 5, pp. 735–742, 2007.

[25] A. Lindholm et al., “Prevalence of symptoms associated with polycystic ovary syndrome,” International Journal of Gynecology and Obstetrics, vol. 102, no. 1, pp. 39–43, 2008.

[26] M. J. Chen, W. S. Yang, J. H. Yang, C. L. Chen, H. N. Ho, and Y. S. Yang, “Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome,” Hypertension, vol. 49, no. 6, pp. 1442–1447, 2007.

[27] M. A. Maturana, V. Breda, F. Lhullier, and P. M. Spritzer, “Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women,” Metabolism, vol. 57, no. 7, pp. 961–965, 2008.

[28] A. D. Coviello, R. S. Legro, and A. Dunaif, “Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 492–497, 2006.

[29] R. Hart, D. A. Doherty, T. Mori et al., “Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome,” Fertility and Sterility, vol. 95, no. 7, pp. 2347–2355.e1, 2011.

[30] B. O. Yildiz, E. S. Knochenhauer, and R. Azziz, “Impact of obesity on the risk for polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 1, pp. 162–168, 2008.

[31] M. Takahashi, K. Shimomura, P. Proks et al., “A proposal of combined evaluation of waist circumference and BMI for the diagnosis of metabolic syndrome,” Endocrine Journal, vol. 56, no. 9, pp. 1079–1082, 2009.

[32] P. A. Essah, E. P. Wickham, and J. E. Nestler, “The metabolic syndrome in polycystic ovary syndrome,” Clinical Obstetrics and Gynecology, vol. 50, no. 1, pp. 205–225, 2007.